Developer of next-gen therapeutics, Greenovation, has increased the yields of pharmaceutical proteins produced using Its moss-based ByroTechnology.
Moss
The technology, used for manufacturing biopharmaceuticals, is a plant based system that takes advantage of a certain type of moss to produce a wide range of biopharmaceutics.
Now, through the company’s ByroMaster cell lines and in conjunction with targeted genetic modifications, improved fermentation procedures and optimised production process, higher levels of complex molecules can be directly secreted into the culture medium, which is used to support the growth of microorganisms.
The production includes antibodies in their active form and sufficient protein can be produced through Greenovation’s ByroSpeed technology.
Dr. Thomas Frischmuth, CEO of Greenovation said: “Our intensive research efforts are now bearing fruit. The recent yield improvements once again underline the viability of moss-based cGMP-production as a beneficial alternative to mammalian cells in steel-tanks.”